Botensilimab and Balstilimab Expanded Access Program
Latest Information Update: 07 Jan 2025
Price :
$35 *
At a glance
- Drugs Balstilimab (Primary) ; Botensilimab (Primary)
- Indications Colorectal cancer; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Sarcoma
- Focus Expanded access; Therapeutic Use
- Sponsors Agenus
- 07 Jan 2025 New trial record